Recursion Pharmaceuticals Inc. has prepared and tested new 1-phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) inhibitors reported to be useful for the treatment of interstitial lung disease, liver, kidney and myocardial fibrosis.

Case Western Reserve University has patented new mitochondrial enhancers potentially useful for the treatment of neurodegeneration.

Hainan Simcere Pharmaceutical Co. Ltd. has described N-myristoyltransferase 1 (NMT1) and NMT2 inhibitors reported to be useful for the treatment of cancer.

Guangzhou Runer Ophthalmic Biotechnology Co. Ltd. has divulged compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy, uveitis, retinitis pigmentosa, atypical hemolytic uremic syndrome, macular edema, membranous glomerulonephritis and paroxysmal nocturnal hemoglobinuria (PNH).

Tianjin Tianyao Pharmaceuticals Co. Ltd. has identified glucocorticoid receptor (GR) agonists reported to be useful for the treatment of conjunctivitis, asthma, chronic obstructive pulmonary disease, allergic rhinitis, nasal polyps, Crohn’s disease, eczema and psoriasis.

Shenzhen Forward Pharmaceutical Co. Ltd. has synthesized quinazoline derivatives acting as GTPase KRAS G12C, G12D and G12V mutant inhibitors reported to be useful for the treatment of pancreatic cancer.

Researchers at Iama Therapeutics Srl and Italian Institute of Technology have disclosed solute carrier family 12 member 2 (SLC12A2; NKCC1) inhibitors reported to be useful for the treatment of Down syndrome.

Crinetics Pharmaceuticals Inc. has described drug conjugates consisting of a non-peptide moiety targeting G protein-coupled receptors (GPCRs) covalently linked to a chemotherapeutic moiety through a linker reported to be useful for the diagnosis and treatment of cancer.

Triana Biomedicines Inc. has divulged protein/nucleic acid degraders acting as cyclin-dependent kinase 2 (CDK2) degraders reported to be useful for the treatment of cancer.

Monash University has identified cyclic peptides acting as melanocortin MC5 receptor (MC5R) agonists reported to be useful for the treatment of diabetes, obesity, cardiomyopathy, heart failure, renal disorders, Rabson Mendenhall syndrome, Donohue syndrome and lipodystrophy.